Recursion Pharmaceuticals (RXRX) has drawn fresh attention after reporting Q4 revenue above consensus, highlighting progress in its AI-native drug discovery platform and a cash runway that management says extends into early 2028.
See our latest analysis for Recursion Pharmaceuticals.
Despite the strong Q4 update and progress across its AI-native programs, Recursion Pharmaceuticals’ share price return has been weak, with a 30 day share price return decline of 10.39% and a 1 year total shareholder return decline of 41.92%. This suggests recent news is being weighed against earlier risk concerns around execution and funding.
If you are interested in how other AI focused names are trading, this could be a good moment to scan 32 AI small caps and see which ones fit your watchlist.
So with Q4 revenue above consensus, a cash runway that management expects into early 2028 and a share price that has lagged, is Recursion trading at a discount to its AI potential, or is the market already pricing in future growth?
Most Popular Narrative: 75.1% Overvalued
Recursion Pharmaceuticals closed at $3.45, while the most followed narrative pegs fair value much lower at $1.97, creating a sharp gap between price and narrative view.
As I see what RXRX did in the 4th quarter I now believe they will be the Palantir of biotechnology one day! Najat Khan the new CEO will lead this company out of the hole created by the former CEO into greatness! She knows how to run a company! Former CEO running RXRX into the ground! GO RECURSION PHARMACEUTICALS!!!!
The fair value in this narrative leans heavily on ambitious revenue expansion, firm profit margins and a future earnings multiple often linked to high growth names. Curious which assumptions drive that gap between $1.97 and today’s price, and how they stack up across time?
Result: Fair Value of $1.97 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this narrative could be challenged if insider activity steadies or clinical programs like REC-4881 and REC-617 reach meaningful milestones that shift sentiment.
Find out about the key risks to this Recursion Pharmaceuticals narrative.
Another View: Our DCF Model Sees Upside
The user narrative points to a fair value of $1.97 and calls RXRX overvalued at $3.45. Our DCF model comes to a very different result, with an estimate of $9.50, which implies RXRX is trading at a large discount. Which set of assumptions do you trust more?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Recursion Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 50 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
With such mixed sentiment around RXRX, it makes sense to move quickly, review the underlying numbers yourself, and weigh 2 key rewards and 2 important warning signs before deciding where you stand.
Looking for more investment ideas?
If RXRX has you thinking harder about where you put your money, do not stop here. Use this momentum to size up a wider set of opportunities.
- Target resilient cash generators by scanning 50 high quality undervalued stocks, which pairs solid fundamentals with prices that may not fully reflect their strengths.
- Strengthen your income stream with 14 dividend fortresses, focusing on companies offering higher yields that could support more predictable cash flow.
- Prioritise staying power by reviewing solid balance sheet and fundamentals stocks screener (41 results), highlighting businesses with cleaner balance sheets and financial flexibility.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com